Aspen, Roche, and Pfizer Face Cancer Drug Pricing Investigation

Aspen, Roche, and Pfizer are looking at a cancer drug pricing investigation. South African regulators are looking into the pharma majors, with the country’s Competition Commission announcing that it had opened probes into the companies for “suspected excessive pricing.” Aspen is the largest generic drug producer in Africa. Regulators will be looking at several drugs, including Herceptin (trastuzumab),  Xalkori (crizotinib), and Aspen’s generic versios of Leukeran (chlorambucil) and Alkeran (melphalan).

Read the source article at BioPharmaDIVE